144 related articles for article (PubMed ID: 28344316)
1. Gain in the short arm of chromosome 2 (2p+) induces gene overexpression and drug resistance in chronic lymphocytic leukemia: analysis of the central role of XPO1.
Cosson A; Chapiro E; Bougacha N; Lambert J; Herbi L; Cung HA; Algrin C; Keren B; Damm F; Gabillaud C; Brunelle-Navas MN; Davi F; Merle-Béral H; Le Garff-Tavernier M; Roos-Weil D; Choquet S; Uzunov M; Morel V; Leblond V; Maloum K; Lepretre S; Feugier P; Lesty C; Lejeune J; Sutton L; Landesman Y; Susin SA; Nguyen-Khac F
Leukemia; 2017 Jul; 31(7):1625-1629. PubMed ID: 28344316
[No Abstract] [Full Text] [Related]
2. Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia.
Lapalombella R; Sun Q; Williams K; Tangeman L; Jha S; Zhong Y; Goettl V; Mahoney E; Berglund C; Gupta S; Farmer A; Mani R; Johnson AJ; Lucas D; Mo X; Daelemans D; Sandanayaka V; Shechter S; McCauley D; Shacham S; Kauffman M; Chook YM; Byrd JC
Blood; 2012 Nov; 120(23):4621-34. PubMed ID: 23034282
[TBL] [Abstract][Full Text] [Related]
3. Recurrent XPO1 mutations alter pathogenesis of chronic lymphocytic leukemia.
Walker JS; Hing ZA; Harrington B; Baumhardt J; Ozer HG; Lehman A; Giacopelli B; Beaver L; Williams K; Skinner JN; Cempre CB; Sun Q; Shacham S; Stromberg BR; Summers MK; Abruzzo LV; Rassenti L; Kipps TJ; Parikh S; Kay NE; Rogers KA; Woyach JA; Coppola V; Chook YM; Oakes C; Byrd JC; Lapalombella R
J Hematol Oncol; 2021 Jan; 14(1):17. PubMed ID: 33451349
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer.
Chen Y; Camacho SC; Silvers TR; Razak AR; Gabrail NY; Gerecitano JF; Kalir E; Pereira E; Evans BR; Ramus SJ; Huang F; Priedigkeit N; Rodriguez E; Donovan M; Khan F; Kalir T; Sebra R; Uzilov A; Chen R; Sinha R; Halpert R; Billaud JN; Shacham S; McCauley D; Landesman Y; Rashal T; Kauffman M; Mirza MR; Mau-Sørensen M; Dottino P; Martignetti JA
Clin Cancer Res; 2017 Mar; 23(6):1552-1563. PubMed ID: 27649553
[No Abstract] [Full Text] [Related]
5. Clinical Implications of Targeting XPO1-mediated Nuclear Export in Multiple Myeloma.
Gandhi UH; Senapedis W; Baloglu E; Unger TJ; Chari A; Vogl D; Cornell RF
Clin Lymphoma Myeloma Leuk; 2018 May; 18(5):335-345. PubMed ID: 29610030
[TBL] [Abstract][Full Text] [Related]
6. The nuclear export protein XPO1 - from biology to targeted therapy.
Azmi AS; Uddin MH; Mohammad RM
Nat Rev Clin Oncol; 2021 Mar; 18(3):152-169. PubMed ID: 33173198
[TBL] [Abstract][Full Text] [Related]
7. Clinical and molecular characteristics of XPO1 mutations in patients with chronic lymphocytic leukemia.
Jain P; Kanagal-Shamanna R; Wierda W; Keating M; Sarwari N; Rozovski U; Thompson P; Burger J; Kantarjian H; Patel KP; Medeiros LJ; Luthra R; Estrov Z
Am J Hematol; 2016 Nov; 91(11):E478-E479. PubMed ID: 27468087
[TBL] [Abstract][Full Text] [Related]
8. Prevalence, distribution and predictive value of XPO1 mutation in a real-life chronic lymphocytic leukaemia cohort.
Tueur G; Lazarian G; Eclache V; Fleury C; Letestu R; Lévy V; Lefebvre V; Collon JF; Zini JM; Thieblemont C; Soussi T; Cymbalista F; Baran-Marszak F
Br J Haematol; 2020 Nov; 191(3):e90-e94. PubMed ID: 32790071
[No Abstract] [Full Text] [Related]
9. Redirecting traffic using the XPO1 police.
Abraham SA; Holyoake TL
Blood; 2013 Oct; 122(17):2926-8. PubMed ID: 24159164
[TBL] [Abstract][Full Text] [Related]
10. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.
Turner JG; Kashyap T; Dawson JL; Gomez J; Bauer AA; Grant S; Dai Y; Shain KH; Meads M; Landesman Y; Sullivan DM
Oncotarget; 2016 Nov; 7(48):78896-78909. PubMed ID: 27806331
[TBL] [Abstract][Full Text] [Related]
11. Identifying drug-target selectivity of small-molecule CRM1/XPO1 inhibitors by CRISPR/Cas9 genome editing.
Neggers JE; Vercruysse T; Jacquemyn M; Vanstreels E; Baloglu E; Shacham S; Crochiere M; Landesman Y; Daelemans D
Chem Biol; 2015 Jan; 22(1):107-16. PubMed ID: 25579209
[TBL] [Abstract][Full Text] [Related]
12. Targeting Cancer at the Nuclear Pore.
Azmi AS; Mohammad RM
J Clin Oncol; 2016 Dec; 34(34):4180-4182. PubMed ID: 27863200
[No Abstract] [Full Text] [Related]
13. Prognostic value and therapeutic targeting of XPO1 in chronic lymphocytic leukemia.
Xu Z; Pan B; Miao Y; Li Y; Qin S; Liang J; Kong Y; Zhang X; Tang J; Xia Y; Zhu H; Wang L; Li J; Wu J; Xu W
Clin Exp Med; 2023 Oct; 23(6):2651-2662. PubMed ID: 36738306
[TBL] [Abstract][Full Text] [Related]
14. Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B-cell lymphoma.
Jardin F; Pujals A; Pelletier L; Bohers E; Camus V; Mareschal S; Dubois S; Sola B; Ochmann M; Lemonnier F; Viailly PJ; Bertrand P; Maingonnat C; Traverse-Glehen A; Gaulard P; Damotte D; Delarue R; Haioun C; Argueta C; Landesman Y; Salles G; Jais JP; Figeac M; Copie-Bergman C; Molina TJ; Picquenot JM; Cornic M; Fest T; Milpied N; Lemasle E; Stamatoullas A; Moeller P; Dyer MJ; Sundstrom C; Bastard C; Tilly H; Leroy K
Am J Hematol; 2016 Sep; 91(9):923-30. PubMed ID: 27312795
[TBL] [Abstract][Full Text] [Related]
15. Chromosome 2p gain in monoclonal B-cell lymphocytosis and in early stage chronic lymphocytic leukemia.
Fabris S; Mosca L; Cutrona G; Lionetti M; Agnelli L; Ciceri G; Barbieri M; Maura F; Matis S; Colombo M; Gentile M; Recchia AG; Anna Pesce E; Di Raimondo F; Musolino C; Gobbi M; Di Renzo N; Mauro FR; Brugiatelli M; Ilariucci F; Lipari MG; Angrilli F; Consoli U; Fragasso A; Molica S; Festini G; Vincelli I; Cortelezzi A; Federico M; Morabito F; Ferrarini M; Neri A
Am J Hematol; 2013 Jan; 88(1):24-31. PubMed ID: 23044996
[TBL] [Abstract][Full Text] [Related]
16. XPO1 Inhibition using Selinexor Synergizes with Chemotherapy in Acute Myeloid Leukemia by Targeting DNA Repair and Restoring Topoisomerase IIα to the Nucleus.
Ranganathan P; Kashyap T; Yu X; Meng X; Lai TH; McNeil B; Bhatnagar B; Shacham S; Kauffman M; Dorrance AM; Blum W; Sampath D; Landesman Y; Garzon R
Clin Cancer Res; 2016 Dec; 22(24):6142-6152. PubMed ID: 27358488
[TBL] [Abstract][Full Text] [Related]
17. XPO1 inhibitors represent a novel therapeutic option in Adult T-cell Leukemia, triggering p53-mediated caspase-dependent apoptosis.
Boons E; Nogueira TC; Dierckx T; Menezes SM; Jacquemyn M; Tamir S; Landesman Y; Farré L; Bittencourt A; Kataoka K; Ogawa S; Snoeck R; Andrei G; Van Weyenbergh J; Daelemans D
Blood Cancer J; 2021 Feb; 11(2):27. PubMed ID: 33563902
[No Abstract] [Full Text] [Related]
18. Selinexor: a first-in-class SINE compound for treatment of relapsed refractory multiple myeloma.
Richard S; Richter J; Jagannath S
Future Oncol; 2020 Jul; 16(19):1331-1350. PubMed ID: 32511022
[TBL] [Abstract][Full Text] [Related]
19. Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors.
Turner JG; Dawson JL; Grant S; Shain KH; Dalton WS; Dai Y; Meads M; Baz R; Kauffman M; Shacham S; Sullivan DM
J Hematol Oncol; 2016 Aug; 9(1):73. PubMed ID: 27557643
[TBL] [Abstract][Full Text] [Related]
20. Novel carfilzomib-based combinations as potential therapeutic strategies for liposarcomas.
Jeitany M; Prabhu A; Dakle P; Pathak E; Madan V; Kanojia D; Mukundan V; Jiang YY; Landesman Y; Tam WL; Kappei D; Koeffler HP
Cell Mol Life Sci; 2021 Feb; 78(4):1837-1851. PubMed ID: 32851475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
